Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. November 2019 08:00 ET | Quelle: Synthorx, Inc.

Synthorx to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
05. November 2019 16:05 ET | Quelle: Synthorx, Inc.

Synthorx Reports Third Quarter Financial Results

SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
05. November 2019 08:00 ET | Quelle: Synthorx, Inc.

Synthorx to Present THOR-809 Data at the American College of Rheumatology (ACR) Annual Meeting

SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
29. Oktober 2019 16:05 ET | Quelle: Synthorx, Inc.

Synthorx to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
23. September 2019 08:00 ET | Quelle: Synthorx, Inc.

Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress

SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
09. September 2019 08:00 ET | Quelle: Synthorx, Inc.

Synthorx to Present at the 2019 World Congress of Inflammation

SAN DIEGO, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
29. August 2019 16:05 ET | Quelle: Synthorx, Inc.

Synthorx to Present at H.C. Wainwright 21st Annual Global Investment Conference

SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
01. August 2019 16:05 ET | Quelle: Synthorx, Inc.

Synthorx Reports Second Quarter Financial Results

SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
24. Juli 2019 08:00 ET | Quelle: Synthorx, Inc.

Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707

SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, announced...
29. Mai 2019 16:10 ET | Quelle: Synthorx, Inc.

Synthorx to Present at Jefferies 2019 Healthcare Conference

SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop...

Nächste Seite